Efficacy and safety of pateclizumab (anti-lymphotoxin-α) compared to adalimumab in rheumatoid arthritis: a head-to-head phase 2 randomized controlled study (The ALTARA Study)

INTRODUCTION: Tumor necrosis factor (TNF) and, possibly, lymphotoxin alpha (LTα) signaling contribute to inflammation and rheumatoid arthritis (RA) pathogenesis. Pateclizumab (anti-lymphotoxin- alpha; MLTA3698A) is a humanized monoclonal antibody that blocks and depletes anti-LTα. This phase 2, rand...

Descripción completa

Detalles Bibliográficos
Autores principales: Kennedy, William P, Simon, J Abraham, Offutt, Carolyn, Horn, Priscilla, Herman, Ann, Townsend, Michael J, Tang, Meina T, Grogan, Jane L, Hsieh, Frank, Davis, John C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243296/
https://www.ncbi.nlm.nih.gov/pubmed/25359150
http://dx.doi.org/10.1186/s13075-014-0467-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4243296/
https://www.ncbi.nlm.nih.gov/pubmed/25359150
http://dx.doi.org/10.1186/s13075-014-0467-3

Ejemplares similares